Business Context and Reporting Period
This Form 8-K was filed by Eyenovia, Inc. (trading symbol: EYEN) on September 26, 2024. The filing reports the entry into a material definitive agreement for a registered direct offering of securities. Note: The request metadata referenced "HYPERION DEFI, INC.", but the filing text explicitly identifies the registrant as Eyenovia, Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered Direct Offering.
- Securities Issued: 8,630,000 shares of Common Stock, 65,653 Pre-Funded Warrants, and 8,695,653 Warrants.
- Offering Price: $0.46 per Share and accompanying Warrant; $0.4599 per Pre-Funded Warrant and accompanying Warrant.
- Expected Gross Proceeds: Approximately $4.0 million.
- Warrant Terms:
- Exercise Price: $0.50 per share.
- Commencement: Six months following issuance.
- Expiration: March 31, 2030.
- Ownership Limitation: 4.99% (unless holder elects 9.99%).
- Pre-Funded Warrant Terms: Immediately exercisable at $0.0001 per share.
Material Changes and Use of Proceeds
The filing does not report historical financial performance changes (revenue, profit, or margins) as this is a current report on a specific transaction. The material change is the dilution of equity and the influx of capital. The Company intends to use net proceeds for:
- Commercialization activities for products Mydcombi and clobetasol propionate.
- Completion of the CHAPERONE pediatric myopia clinical study.
- Working capital and general corporate purposes.
- Potential repayment of amounts outstanding under a Loan and Security Agreement with Avenue Capital Management II, L.P.
Outlook, Risks, and Management Commentary
Outlook: The Offering is expected to close on or about September 30, 2024, subject to customary closing conditions. Placement agents include A.G.P./Alliance Global Partners and Brookline Capital Markets.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual outcomes may differ due to risks regarding the completion of the Offering, regulatory approvals for product candidates, and market conditions. The Company does not undertake an obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received (expected ~$4.0 million).
- Confirm the exact amount of debt repayment to Avenue Capital Management II, L.P., if any proceeds are allocated there.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification obligations.
- Monitor the progress of the CHAPERONE pediatric myopia clinical study as a key use of funds.
- Check subsequent filings for the actual issuance of shares and warrants and any changes to the ownership limitation elections by the investor.